This is a demo store. No orders will be fulfilled.
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
10 May 2018  |  North America  |  Market Research
Global Tissue Diagnostics Market, Forecast to 2022
Liquid Biopsy for Therapy Monitoring and Reimbursement Cuts Impede Long-term Prospects of Tissue Diagnostics Market
Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pat...
$4,950.00 -
09 Apr 2018  |  North America  |  Market Outlook
Global Life Sciences Industry Outlook, 2018
Global Life Sciences Industry to Reach $1.5 T by 2022, Driven by Innovative Google, Amazon, Facebook, Apple (GAFA) Partnerships and R&D IT Investments
The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...
$4,950.00 -
15 Feb 2018  |  Global  |  Market Research
Global Laboratory Products Purchasing Trends, 2017–2018
An End User Perspective on Laboratory Spending Reveals Optimism for Growing 2018 Budgets
Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in July 2017 that centered around the state of their laboratories in 2017 and their expectations for 2018. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-over...
$1,500.00 -
06 Feb 2018  |  Global  |  Mega Trends
Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020
Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows
The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...
$4,950.00 -
10 Jan 2018  |  Asia Pacific  |  Mega Trends
APAC Biosimilar Market, Forecast 2025
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...
$4,950.00 -
21 Dec 2016  |  Africa  |  Market Research
African Pharmaceuticals Market, Forecast to 2020
Assessing Market Potential with a Focus on Kenya and Nigeria
The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...
$4,950.00 -
19 Dec 2016  |  Global  |  Customer Research
Global Laboratory Products Purchasing Trends, 2016–2017
An End-user Perspective on the Purchasing Process, Product Budgets, and Top Companies for Laboratory Products
Readers of Lab Manager Magazine were invited to participate in an online survey in July 2016. To qualify for survey participation, readers had to play a role in their laboratory’s purchasing process, be familiar with their laboratory’s product budgets, and represent a laboratory that either uses or plans to use products in 1 or more of the 7 sp...
$6,000.00 -
14 Nov 2016  |  Asia Pacific  |  Market Research
Analysis of the Indonesian Clinical Laboratories Market
Increase in Test Volumes Due to Universal Health Coverage will Boost Market Growth Across All Segments
Given the ever-increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from health settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinic laboratory diagnostics. Effective delivery of healthcare services has created a business and technology convergence be...
$1,500.00 -
11 Nov 2016  |  North America  |  Market Research
Global Orphan Drug Market
High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs
The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...
$6,000.00 -
11 Nov 2016  |  Asia Pacific  |  Market Research
Analysis of the Australian Clinical Laboratory Market
Evolving Business Model—Technological Advances will Drive the Market
Given the ever increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from healthcare settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinical laboratory diagnostics. The effective delivery of healthcare services has created a business and technology conv...
$1,500.00